Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT010
MIFTS: 54

Diabetic Neuropathy

Categories: Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diabetic Neuropathy

About this section

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 12 73 53 36 15 37 17
Diabetic Neuropathies 54 70

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9743
KEGG 36 H01459
ICD9CM 34 250.6
MeSH 44 D003929
NCIt 50 C26748
SNOMED-CT 67 193182005
UMLS 70 C0011882
Sources

Summaries for Diabetic Neuropathy

About this section
NINDS : 53 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary : Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 2, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and PEDF Induced Signaling. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, endothelial and dorsal root ganglion, and related phenotypes are Increased the percentage of infected cells and behavior/neurological

KEGG : 36 Diabetic neuropathies (DNs) are nerve damaging disorders caused by diabetes. Diabetic neuropathy broadly comprise generalized symmetric polyneuropathies (acute sensory, chronic sensorimotor, autonomic) and asymmetric (focal and multifocal) neuropathies (cranial, truncal, focal-limb, proximal-motor, coexisting chronic inflammatory demyelinating), which affect all organs and system. Of all types, diabetic sensorimotor polyneuropathy (DSPN), also called distal symmetric neuropathy, is the most typical form. Typical Symptoms vary from person to person, but may include numbness, tingling, pain, or weakness that typically starts in the feet and progresses up the legs. This pattern of neuropathy shows a progressive distal axonopathy. It has been reported that vascular endothelial growth factor A is associated with DNs development and progression.

Wikipedia : 73 Diabetic neuropathy refers to various types of nerve damage associated with diabetes mellitus. Symptoms... more...

Sources

Related Diseases for Diabetic Neuropathy

About this section

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.6 VEGFA INS EPO AKR1B1
2 microvascular complications of diabetes 2 32.3 EPO ACE
3 microvascular complications of diabetes 3 32.1 INS AKR1B1 AGER ACE
4 type 1 diabetes mellitus 32.1 VEGFA SOD2 INS AKR1B1 ACE
5 microvascular complications of diabetes 5 31.7 VEGFA SORD SOD2 PRKCB INS AKR1B1
6 type 2 diabetes mellitus 31.6 VEGFA SOD3 SOD2 PRKCB INS EPO
7 hyperglycemia 31.4 SORD SOD2 PRKCB INS AKR1B1 AGER
8 diabetic autonomic neuropathy 31.3 NTF3 NGF INS EPO AKR1B1 ACE
9 diabetic polyneuropathy 31.2 VEGFA SOD3 SOD2 NTF3 NGF INS
10 mononeuropathy 31.0 TRPV1 PMP22 NGF MPZ
11 autonomic neuropathy 31.0 SCN9A NTRK1 NTF3 NGF INS EPO
12 vascular disease 30.9 VEGFA INS EPO AGER ACE
13 polyneuropathy 30.9 VEGFA PMP22 NGF MPZ INS GDNF
14 proteinuria, chronic benign 30.7 VEGFA INS ACE
15 neuropathy 30.7 VEGFA TRPV1 SORD SOD2 SCN9A PMP22
16 wallerian degeneration 30.7 VEGFA MPZ CNTF
17 sexual disorder 30.7 VEGFA INS ACE
18 pain agnosia 30.7 TRPV1 SCN9A NGF
19 carpal tunnel syndrome 30.6 VEGFA PMP22 MPZ INS ACE
20 sleep apnea 30.6 VEGFA INS EPO ACE
21 diabetes mellitus 30.6 VEGFA SORD SOD3 SOD2 PRKCB INS
22 constipation 30.5 TRPV1 NTF3 INS GDNF AKR1B1
23 uremia 30.4 INS EPO ACE
24 demyelinating polyneuropathy 30.4 PMP22 NGF GDNF
25 anhidrosis 30.4 NTRK1 NGFR NGF
26 neuritis 30.3 VEGFA PMP22 MPZ GDNF CNTF
27 cataract 30.3 VEGFA SORD SOD2 INS AKR1B1 ACE
28 diabetic encephalopathy 30.2 NGF INS GDNF
29 burning mouth syndrome 30.2 TRPV1 SCN9A NGF
30 algoneurodystrophy 30.2 NGF INS
31 silent myocardial infarction 30.2 INS ACE
32 apnea, obstructive sleep 30.2 VEGFA INS ACE
33 sensory peripheral neuropathy 30.2 TRPV1 SCN9A PMP22 NTRK1 NTF3 NGF
34 diabetic angiopathy 30.1 SOD2 INS AGER
35 ischemic neuropathy 30.1 VEGFA CNTF
36 atherosclerosis susceptibility 30.0 VEGFA INS AGER ACE
37 ischemia 30.0 VEGFA SOD2 EPO ACE
38 neurogenic arthropathy 30.0 SCN9A NTRK1 NGF INS
39 paine syndrome 30.0 TRPV1 SCN9A NGF
40 demyelinating disease 30.0 PMP22 NTF3 NGF MPZ CNTF
41 nerve compression syndrome 30.0 TRPV1 PMP22 NGF MPZ INS
42 kidney disease 29.9 VEGFA PRKCB INS EPO AKR1B1 AGER
43 peripheral nervous system disease 29.9 VEGFA TRPV1 SCN9A PMP22 NTRK1 NTF3
44 nervous system disease 29.8 VEGFA NGF INS GDNF ACE
45 trigeminal neuralgia 29.8 TRPV1 SCN9A NTRK1 NGF
46 body mass index quantitative trait locus 11 29.8 VEGFA TRPV1 SOD2 INS CNTF AKR1B1
47 amyotrophic lateral sclerosis 1 29.7 VEGFA SOD2 NTRK1 NTF3 NGFR NGF
48 myocardial infarction 29.7 VEGFA SOD3 INS EPO AGER ACE
49 motor neuron disease 29.7 VEGFA SOD2 NTF3 MPZ INS GDNF
50 charcot-marie-tooth disease 29.6 SCN9A PMP22 NTRK1 NTF3 NGF MPZ

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy
Sources

Symptoms & Phenotypes for Diabetic Neuropathy

About this section

UMLS symptoms related to Diabetic Neuropathy:


sciatica; neuralgia

GenomeRNAi Phenotypes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased the percentage of infected cells GR00402-S-1 8.32 TRPV1

MGI Mouse Phenotypes related to Diabetic Neuropathy:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 ACE AGER AKR1B1 CNTF GDNF INS
2 homeostasis/metabolism MP:0005376 10.41 ACE AGER AKR1B1 CNTF EPO INS
3 growth/size/body region MP:0005378 10.36 ACE AGER AKR1B1 GDNF INS NGF
4 cardiovascular system MP:0005385 10.35 ACE AGER EPO GDNF INS NGF
5 immune system MP:0005387 10.33 ACE AGER CNTF EPO GDNF INS
6 mortality/aging MP:0010768 10.28 ACE AKR1B1 EPO GDNF INS MPZ
7 hematopoietic system MP:0005397 10.27 ACE AGER CNTF EPO GDNF INS
8 cellular MP:0005384 10.26 AGER CNTF EPO GDNF INS MPZ
9 nervous system MP:0003631 10.2 ACE CNTF GDNF INS MPZ NGF
10 muscle MP:0005369 10.18 AGER CNTF EPO GDNF INS NGF
11 integument MP:0010771 10.17 AGER EPO INS MPZ NGF NGFR
12 normal MP:0002873 9.9 AGER EPO INS NGF NGFR NTF3
13 no phenotypic analysis MP:0003012 9.8 CNTF INS NGF NTRK1 SOD3 TRPV1
14 renal/urinary system MP:0005367 9.65 ACE AGER AKR1B1 GDNF INS NGFR
15 vision/eye MP:0005391 9.36 ACE AKR1B1 INS NGF NGFR NTF3
Sources

Drugs & Therapeutics for Diabetic Neuropathy

About this section

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
3
Capsaicin Approved Phase 4 404-86-4 1548943
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Amitriptyline Approved Phase 4 50-48-6 2160
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
12
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
13
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
14
Cetirizine Approved Phase 4 83881-51-0 2678
15
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
16
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
17
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
18
Donepezil Approved Phase 4 120014-06-4 3152
19
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
20
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
26
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
27
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
28
Cobalamin Experimental Phase 4 13408-78-1 6857388
29 Antihypertensive Agents Phase 4
30 Anti-Arrhythmia Agents Phase 4
31 Vitamin B9 Phase 4
32 Trace Elements Phase 4
33 Nutrients Phase 4
34 Vitamins Phase 4
35 Vitamin B 12 Phase 4
36 Vitamin B Complex Phase 4
37 Folate Phase 4
38 Vitamin B12 Phase 4
39 Micronutrients Phase 4
40 Anesthetics Phase 4
41 abobotulinumtoxinA Phase 4
42 Botulinum Toxins Phase 4
43 Botulinum Toxins, Type A Phase 4
44 insulin Phase 4
45 Hypoglycemic Agents Phase 4
46 Insulin, Globin Zinc Phase 4
47 Calciferol Phase 4
48 Antipyretics Phase 4
49 Alpha-lipoic Acid Phase 4
50 Thioctic Acid Phase 4

Interventional clinical trials:

(show top 50) (show all 436)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
2 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
3 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
4 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
5 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Completed NCT03271151 Phase 4 Cymbalta
6 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
7 A Multicenter Trial Evaluating the Efficacy of Cesametâ„¢ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesametâ„¢ (nabilone)
8 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
9 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
10 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
11 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
12 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
13 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
14 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
15 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
16 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
17 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
18 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
19 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapyâ„¢ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
20 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
21 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
22 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
23 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
24 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
25 Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of Tegretol® in Diabetes Neuropathy Pain. Completed NCT01089855 Phase 4 Carbamazepine
26 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
27 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
28 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
29 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
30 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
31 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
32 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
33 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
34 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
35 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
36 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
37 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
38 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
39 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
40 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
41 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
42 Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM) Recruiting NCT04246619 Phase 4 Pregabalin;Duloxetine
43 Effect of High-Dose N-acetyl Cysteine (NAC) on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy (DPN) Not yet recruiting NCT04766450 Phase 4 Acetyl cysteine
44 Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain Terminated NCT01743976 Phase 4 Donepezil;Placebo
45 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
46 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
47 A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Terminated NCT02156336 Phase 4 Ranolazine;Placebo
48 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
49 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months. Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
50 A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy Unknown status NCT00134524 Phase 3

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Becaplermin
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
mecobalamin
Mexiletine
Mexiletine Hydrochloride
Pentoxifylline
Vitamin B 12

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)
Sources

Genetic Tests for Diabetic Neuropathy

About this section
Sources

Anatomical Context for Diabetic Neuropathy

About this section

MalaCards organs/tissues related to Diabetic Neuropathy:

40
Spinal Cord, Endothelial, Dorsal Root Ganglion, Skin, Bone Marrow, Pancreas, Eye
Sources

Publications for Diabetic Neuropathy

About this section

Articles related to Diabetic Neuropathy:

(show top 50) (show all 7050)
# Title Authors PMID Year
1
Therapeutic strategies for diabetic neuropathy. 54 61
20425233 2010
2
A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus. 54 61
19601918 2009
3
Expression of neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength. 61 54
19696031 2009
4
Neuropathy is associated with depression independently of health-related quality of life in Japanese patients with diabetes. 54 61
19067994 2009
5
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective. 54 61
19893679 2008
6
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. 54 61
18644069 2008
7
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. 54 61
18447661 2008
8
Aldose reductase, still a compelling target for diabetic neuropathy. 54 61
18220710 2008
9
Pharmacologic intervention in axonal excitability: in vivo assessment of nodal persistent sodium currents in human neuropathies. 54 61
20021424 2008
10
Epidemiology and management of type 1 diabetes mellitus at the ain shams university pediatric hospital. 54 61
18992206 2008
11
sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. 54 61
18046662 2007
12
Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients. 54 61
17492429 2007
13
Pyridine nucleotide redox abnormalities in diabetes. 61 54
17508915 2007
14
Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. 54 61
17521436 2007
15
Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. 54 61
17327338 2007
16
Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. 61 54
17187935 2007
17
Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. 54 61
17063327 2006
18
Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. 61 54
17070440 2006
19
Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. 61 54
18220622 2006
20
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics. 61 54
16717216 2006
21
Advanced Diabetic Neuropathy: A Point of no Return? 61 54
17487338 2006
22
Induction of heat shock proteins may combat insulin resistance. 54 61
16309849 2006
23
Talin immunogold density increases in sciatic nerve of diabetic rats after nerve growth factor treatment. 54 61
16528132 2006
24
Are Type 2 diabetic patients offered adequate foot care? The role of physician and patient characteristics. 54 61
16260348 2005
25
Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. 61 54
16268804 2005
26
The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents. 61 54
16176189 2005
27
A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. 54 61
16112498 2005
28
Retinoic acid increases tissue and plasma contents of nerve growth factor and prevents neuropathy in diabetic mice. 61 54
15733075 2005
29
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? 54 61
15539002 2004
30
C-peptide: much more than a byproduct of insulin biosynthesis. 61 54
15367890 2004
31
Direct insulin signaling of neurons reverses diabetic neuropathy. 54 61
15220207 2004
32
Biochemical pharmacology of the vanilloid receptor TRPV1. An update. 61 54
15128291 2004
33
Aldose reductase structures: implications for mechanism and inhibition. 61 54
15095000 2004
34
Outcomes of decompression surgery for lumbar spinal stenosis in elderly diabetic patients. 54 61
14614597 2004
35
Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy. 54 61
14989368 2004
36
Neurotrophic factors and their receptors in human sensory neuropathies. 54 61
14699981 2004
37
Clinical potential of aldose reductase inhibitors in diabetic neuropathy. 61 54
16026107 2004
38
New insights into the metabolic and molecular basis for diabetic neuropathy. 61 54
14625688 2003
39
Fidarestat. Sanwa Kagaku/NC Curex/Sankyo. 54 61
14649216 2003
40
Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. 61 54
12924487 2003
41
Genetic analysis of aldose reductase in diabetic complications. 54 61
12871135 2003
42
Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. 54 61
12805110 2003
43
Selective decrease in axonal nerve growth factor and insulin-like growth factor I immunoreactivity in axonopathies of unknown etiology. 54 61
12677448 2003
44
Acute painful neuropathy (insulin neuritis) in a boy following rapid glycemic control for type 1 diabetes mellitus. 61 54
12822825 2003
45
Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. 54 61
12638730 2003
46
A thematic approach to enhance clinical content in a cell and tissue biology course. 61 54
12431955 2002
47
Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? 61 54
12198818 2002
48
Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. 61 54
11779407 2001
49
Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. 54 61
11701599 2001
50
Diabetic neuropathy: pathogenetic background, current and future therapies. 61 54
19811034 2001
Sources

Variations for Diabetic Neuropathy

About this section
Sources

Expression for Diabetic Neuropathy

About this section
Search GEO for disease gene expression data for Diabetic Neuropathy.
Sources

Pathways for Diabetic Neuropathy

About this section

Pathways related to Diabetic Neuropathy according to KEGG:

36
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933

Pathways related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 63
Show member pathways
 13.5 SOD2 PRKCB NTRK1 NGFR NGF INS
2
p70S6K Signaling 63
Show member pathways
 12.86 PRKCB NTRK1 NTF3 NGFR NGF INS
3
PI3K-Akt signaling pathway 36
Show member pathways
 12.75 VEGFA NTRK1 NTF3 NGFR NGF INS
4
Beta-Adrenergic Signaling 63
Show member pathways
 12.64 PRKCB NGFR NGF INS EPO
5
Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases 23
Show member pathways
 12.43 NTRK1 NTF3 NGFR NGF
6
MAPK signaling pathway 36 1
12.37 VEGFA PRKCB NTRK1 NTF3 NGFR NGF
7
Calcium signaling pathway 36
12.18 VEGFA PRKCB NTRK1 NGF GDNF
8
Ras signaling pathway 36
Show member pathways
 12.15 VEGFA PRKCB NTRK1 NTF3 NGFR NGF
9
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.1 PRKCB NTRK1 NTF3 NGFR NGF
10
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.94 NTRK1 NTF3 NGFR NGF
11
HIF-1 signaling pathway 36
11.8 VEGFA PRKCB INS EPO
12
AGE-RAGE signaling pathway in diabetic complications 36
11.76 VEGFA PRKCB AGER
13
TNF Superfamily Pathway: Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.65 NTF3 NGFR NGF
14
p75(NTR)-mediated signaling 1
Show member pathways
 11.53 NTF3 NGFR NGF
15
AGE/RAGE pathway 1
11.52 PRKCB INS AGER
16
Neurotrophic factor-mediated Trk receptor signaling 1
Show member pathways
 11.41 NTRK1 NTF3 NGFR NGF
17
Differentiation Pathway 1
11.24 VEGFA INS EPO CNTF
18
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
10.92 VEGFA NTF3 NGF GDNF CNTF
19
Activation of TRKA receptors 65
Show member pathways
 10.61 NTRK1 NGF
Sources

GO Terms for Diabetic Neuropathy

About this section

Cellular components related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFA SOD3 NTF3 NGFR NGF INS
2 axon GO:0030424 9.55 SCN9A NTRK1 NTF3 NGF CNTF
3 Golgi lumen GO:0005796 9.43 SOD3 NGF INS
4 extracellular space GO:0005615 9.36 VEGFA SORD SOD3 NTF3 NGF INS

Biological processes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.01 VEGFA NTF3 INS GDNF EPO CNTF
2 nervous system development GO:0007399 9.99 VEGFA NTRK1 NTF3 NGFR GDNF CNTF
3 positive regulation of cell migration GO:0030335 9.91 VEGFA SOD2 NTF3 INS
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 VEGFA NTRK1 EPO AGER
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 PRKCB NTRK1 INS AGER
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 VEGFA NTF3 NGF
7 response to nutrient levels GO:0031667 9.78 SORD SOD2 NTRK1
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 VEGFA EPO CNTF
9 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.77 VEGFA NGFR NGF
10 response to hypoxia GO:0001666 9.77 VEGFA SOD3 SOD2 EPO AGER
11 sensory perception of pain GO:0019233 9.75 TRPV1 SCN9A NTRK1
12 cellular response to amyloid-beta GO:1904646 9.72 NTRK1 NGFR AGER
13 positive regulation of Ras protein signal transduction GO:0046579 9.7 NTRK1 NGF EPO
14 response to electrical stimulus GO:0051602 9.67 SOD2 NTRK1 EPO
15 sympathetic nervous system development GO:0048485 9.65 NTRK1 GDNF
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 VEGFA NTRK1 NTF3 INS EPO
17 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.64 SOD2 INS
18 removal of superoxide radicals GO:0019430 9.64 SOD3 SOD2
19 commissural neuron axon guidance GO:0071679 9.63 VEGFA GDNF
20 neurotrophin TRK receptor signaling pathway GO:0048011 9.63 NTRK1 NGFR NGF
21 behavioral response to pain GO:0048266 9.62 TRPV1 SCN9A
22 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.62 NGFR NGF
23 induction of positive chemotaxis GO:0050930 9.61 VEGFA NTF3 AGER
24 nerve development GO:0021675 9.58 NTF3 NGFR NGF
25 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.57 VEGFA ACE
26 nerve growth factor signaling pathway GO:0038180 9.5 NTRK1 NTF3 NGF
27 fructose biosynthetic process GO:0046370 9.48 SORD AKR1B1
28 peripheral nervous system development GO:0007422 9.46 PMP22 NTF3 NGF GDNF
29 negative regulation of neuron apoptotic process GO:0043524 9.43 SOD2 NTRK1 NTF3 NGF GDNF CNTF
30 negative regulation of apoptotic process GO:0043066 9.28 VEGFA SOD2 NTRK1 NGFR NGF MPZ

Molecular functions related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nerve growth factor binding GO:0048406 9.32 NTRK1 NGFR
2 nerve growth factor receptor binding GO:0005163 9.26 NTF3 NGF
3 superoxide dismutase activity GO:0004784 9.16 SOD3 SOD2
4 growth factor activity GO:0008083 9.02 VEGFA NTF3 NGF GDNF CNTF
5 neurotrophin binding GO:0043121 8.96 NTRK1 NGFR
Sources

Sources for Diabetic Neuropathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....